Prenosis

Breaking News! Prenosis — an artificial intelligence company enabling precision medicine in acute care — is proud to announce that the FDA has granted marketing authorization (De Novo pathway) for the Sepsis ImmunoScore™, our AI diagnostic and predictive tool for early detection of sepsis. This signifies the first-ever FDA marketing authorization of an AI diagnostic tool for sepsis. Sepsis, a complex and deadly condition, claims more lives than all cancers combined. https://lnkd.in/g-crKfn6 Join us in celebrating this historic “first" for healthcare innovation! #Sepsis #AI #FDAApproval #Prenosis 

Thrilled to announce that our groundbreaking study has been published in the NEJM AI: https://lnkd.in/gZvaYFWN The paper highlights the predictive power of Sepsis ImmunoScore™. Prenosis' Sepsis ImmunoScore™—the first FDA-authorized AI diagnostic tool for sepsis—not only demonstrates high accuracy in diagnosing sepsis but also shows significant predictive power for key adverse patient outcomes. This marks a monumental step forward in sepsis care, highlighting the transformative potential of #AI in healthcare. Sepsis claims the lives of at least 350,000 people annually in the U.S.—more than all cancers combined—and costs the healthcare system billions of dollars each year. With the Sepsis ImmunoScore™, we're ushering in a new era of predictive tools powered by AI, moving from reactive treatment to proactive management. A heartfelt thank you to our incredible team at Prenosis and all our collaborators who made this possible. Together, we're advancing the era of prenostics, where AI doesn't just diagnose—it anticipates. Learn more about our study and join us in transforming patient care. #AI #SepsisCare #HealthcareInnovation #Prenosis #SepsisImmunoScore #NEJMAI

Heading to the #IHIForum in Orlando, December 8-11? Prenosis will be there, showcasing how our FDA-authorized Sepsis ImmunoScore™ helps providers improve SEP-1 bundle compliance. Stop by Booth #416 to discover how our innovative approach to precision diagnostics is transforming sepsis care. We’re excited to connect and share insights with the healthcare quality community. #PrecisionDiagnostics #SepsisCare #HealthcareInnovation

We are thrilled to announce that our Sepsis ImmunoScore™ has been recognized as one of TIME's Best Inventions of 2024! We are honored to be featured among the world’s most transformative inventions. With thousands of submissions from across the globe, it’s an incredible achievement to stand out in such prestigious company. The Sepsis ImmunoScore™ is the first FDA-authorized AI diagnostic for sepsis, a groundbreaking achievement that marks a new era in precision diagnostics. This recognition is a testament to the incredible dedication of our Prenosis team, as well as the collaboration with our healthcare partners who continue to trust and believe in the power of innovation to save lives. Thank you to everyone who has been part of this journey. You can read the TIME article here: https://lnkd.in/gzj9erxz #TIMEBestInventions #SepsisImmunoScore #PrecisionDiagnostics #AIInHealthcare #SepsisAwareness #InnovationInHealthcare #Prenosis #HealthcareInnovation

Sepsis continues to be one of the leading causes of preventable deaths in healthcare, with up to 1.7 million cases each year in the U.S. alone, resulting in nearly 270,000 fatalities. The recent Agency for Healthcare Research and Quality (AHRQ) report on sepsis care shines a spotlight on these figures, encouraging us to come together to identify and treat sepsis earlier and more effectively. The report emphasizes the importance of early recognition and swift intervention, which can significantly improve patient outcomes and reduce mortality. https://lnkd.in/eXCDcqdG

In the recently published JAMA article, "FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine," three prominent FDA officials highlighted Prenosis and the Sepsis ImmunoScore™—the first-ever FDA-authorized AI diagnostic for sepsis—as a key example of successfully navigating the FDA’s regulatory process. JAMA, the most widely circulated general medical journal in the world, serves as an influential platform for discussing critical advancements in healthcare, further underscoring the significance of this recognition. As the FDA focuses on ensuring #AI tools are safe, effective and trustworthy, Prenosis is honored and excited to be recognized. Following the FDA framework not only guarantees safety and efficacy but also drives innovation. At Prenosis, we are proud to be at the forefront of this movement, striving to make precision medicine the standard of care for serious hospital conditions. Achieving FDA authorization for the Sepsis ImmunoScore™ through the De Novo pathway—an even more rigorous process than the 510(k) approval, which relies on existing predicate devices—demonstrates our commitment to regulatory excellence, safety, and innovation. This achievement continues to position the Sepsis ImmunoScore™ as a unique and groundbreaking AI-powered tool for sepsis. Read the article by FDA officials Haider J. Warraich, MD; Troy Tazbaz; and Robert M. Califf, MD: https://lnkd.in/giCD5fC5

Be sure you don't miss your opportunity to see the #Sepsis ImmunoScore, the first-ever AI Sepsis diagnostic, that is available on the #navify Algorithm Suite at #HLTH24!

Let's Connect! I'm attending HLTH 2024, happening Oct 20 - 23 in Las Vegas. You can find me at Booth 1532 or you can message me directly. Come by and check out the #SepsisImmunoScore by Prenosis - the first FDA Authorized Sepsis #AI Diagnostic! #Sepsis #HLTHUSA #healthcareinnovation #healthcare #bebold

Join us on October 17 at the Arizona State University's Annual National Diagnostics Summit panel, “The AI Revolution: Preparing for the Future,” featuring Prenosis’ Carlos Lopez-Espina, Tempus AI’s Ezra Cohen, ASU College of Health Solutions Hassan Ghasemzadeh, and Abbott Laboratories’ Brian Renley. The panel will be moderated by Arizona State University’s Travis Schlappi. Carlos will discuss AI’s impact on healthcare and highlight the FDA authorization of the Sepsis ImmunoScore™, the first-ever FDA-authorized #AI diagnostic for #sepsis. To build the Sepsis ImmunoScore™, Prenosis leveraged its Immunix™ #AI platform and proprietary biobank/dataset, which includes more than 110,000 blood samples from over 27,000 patients. Immunix™ and the dataset—the world’s largest for acute care patients suspected of having serious infections—have the potential to be used to develop AI biomarkers beyond the Sepsis ImmunoScore™. Don’t miss this opportunity to learn about the future of AI in healthcare. Register here: https://lnkd.in/e9s2vPMr Event Details: 📅 Thursday, October 17, 2024 ⏰ 11:30 am to 12:15 pm 🌍 Location: Health Futures Center, 6161 East Mayo Blvd., Scottsdale, AZ

We are incredibly proud to share that Prenosis CEO Bobby Reddy, Jr. has been recognized by Crain's Chicago Business as a 40 Under 40 honoree! This prestigious award highlights Bobby’s visionary leadership in advancing precision medicine. Thank you, Crain's Chicago Business, for acknowledging Bobby’s dedication and Prenosis' commitment to reshaping healthcare. We're excited to continue driving impactful change in patient care. #Leadership #HealthcareInnovation #AI #PrecisionMedicine #Sepsis #Diagnostics #40Under40 #CrainsChicago